News
KZIA
1.010
-0.98%
-0.010
Why Calyxt Shares Are Trading Higher By Around 116%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Benzinga · 01/17 18:21
Neovasc, Aligos top healthcare gainers; Edesa, Angion lead losers' pack
Seeking Alpha · 01/17 15:00
Kazia to Raise AU$4.5 Million in Private Placement of Shares
Kazia to Raise AU$4.5 Million in Private Placement of Shares
MT Newswires · 01/17 05:19
Kazia raises A$4.5M to progress R&D programs
Seeking Alpha · 01/16 13:33
Kazia Therapeutics Seeks Trading Halt Pending Announcement On Anticipated Financing Transaction
Benzinga · 01/11 22:09
Reported Late Monday, Kazia Therapeutics Announces Research Collaboration With QIMR Berghofer Medical Research Institute To Investigate The Utility Of Its Lead Asset, Paxalisib In Solid Tumors
Benzinga · 12/20/2022 05:56
Kazia Therapeutics Teams Up With Cancer Research Center in Australia to Study Paxalisib as Combination Therapy
Kazia Therapeutics Teams Up With Cancer Research Center in Australia to Study Paxalisib as Combination Therapy
MT Newswires · 12/20/2022 05:05
Kazia Launches Preclinical Collaboration With Qimr Berghofer Medical Research Institute and Announces Patent Filing
Benzinga · 12/14/2022 22:52
Kazia Announces Receipt Of Nasdaq Minimum Bid Notification
Benzinga · 12/12/2022 12:05
Kazia Therapeutics Gets Nasdaq Warning on Minimum Bid Price Rule; Shares Drop
Kazia Therapeutics Gets Nasdaq Warning on Minimum Bid Price Rule; Shares Drop
MT Newswires · 12/12/2022 10:51
COMPELLING PRECLINICAL DATA FOR KAZIA'S EVT801 PUBLISHED IN PEER-REVIEWED CANCER RESEARCH JOURNAL
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the publication of positive preclinical data for EVT801, a clinical-stage drug candidate currently in a clinical trial for multiple fo...
PR Newswire · 12/01/2022 12:01
Quite a few insiders invested in Kazia Therapeutics Limited (ASX:KZA) last year which is positive news for shareholders
It is usually uneventful when a single insider buys stock. However, When quite a few insiders buy shares, as it...
Simply Wall St. · 11/28/2022 21:50
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 11/23/2022 13:07
KAZIA TO PRESENT PAXALISIB DATA IN ADULT AND PEDIATRIC BRAIN CANCER AT SOCIETY FOR NEURO-ONCOLOGY ANNUAL MEETING
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, today announced that final data from its phase II study of paxalisib in patients with newly diagnosed glioblastoma will be the subject of an oral presentatio...
PR Newswire · 11/09/2022 12:00
Kazia Therapeutics provides cash outlook
Seekingalpha · 11/02/2022 14:44
Kazia Therapeutics (KZIA): Q123 Cash Flows in Line with Our Estimates
Kazia Therapeutics' Q123 cash flow report provided an update on the company's financial position and business progress. While the quarter was dominated by lead asset paxalisib hitting a roadblock (failing to graduate to stage two of the GBM AGILE study), t...
ACCESSWIRE · 11/02/2022 11:10
Why Quanergy Systems Shares Are Trading Sharply Lower; Here Are 28 Stocks Moving Premarket
Benzinga · 10/31/2022 10:36
12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga · 10/28/2022 17:59
12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga · 10/28/2022 12:09
Kazia Therapeutics Reveals Paxalisib Preclinical Data In Melanoma Animal Models
Benzinga · 10/27/2022 14:48
More
Webull provides a variety of real-time KZIA stock news. You can receive the latest news about Kazia Therapeuti through multiple platforms. This information may help you make smarter investment decisions.
About KZIA
Kazia Therapeutics Limited is an Australia-based oncology-focused biotechnology company. The Company is engaged in pharmaceutical research and development. The Company’s drug candidates are designed to treat diseases such as brain cancer, renal cancer, and liver cancer. The Company’s lead programs include paxalisib and EVT801. Paxalisib is a small molecule, brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, a central regulator of growth and cell division that is dysregulated in many types of cancer. Paxalisib is being developed for several forms of brain cancer. EVT801 is a small molecule inhibitor of vascular endothelial growth factor receptor 3 (VEGFR3). EVT801 is being developed in patients with advanced cancer. EVT801 targets angiogenesis, the formation of new blood vessels around a tumor.